SecBot SecBot

GYRE

GYRE THERAPEUTICS, INC.
Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0001124105 Biotech & Drug Discovery
$6.07 +0.22 (+3.76%)
Oct 26 4:00 PM ET · prev $5.85
Market cap
$653.4M
Small cap
Median target
$18.00
+197% · range $18.00–20.00
Next earnings
Nov 18
in 23 days · EPS est. −$0.12
1 year
−24.3%
from $8.02 · Oct 27
30 days
−19.0%
from $7.49
52-week range
$5.56–8.76
−31% from high · low Jun 2
Avg volume 20D
126.9K
shares / day
Short interest
🔒 Subscribers only
Insider net
−$907.2K
0 buyers · 2 sellers · 12 mo
New fund stakes
0
Q2 2026 13F · 0 exits
Filing reports
10
analyzed by SecBot
SecBot read MIXED 5 reports · 90 days
Balance 1 bearish · 0 bullish · 4 neutral oldest → newest, height = score
Avg score ·High conf. 3/5 ·Next Earnings date, Nov 18, 2026
Strongest NEUTRAL Gyre Therapeutics entered into formal employment agreements with CEO Ying Luo and CFO Thomas Eastling on…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersBEARISH

    2 insiders sold $907.2K.

  • InstitutionsBULLISH

    Q2 2026: 17 added (0 new), 2 trimmed or exited.

  • EstimatesFALLING

    Current-quarter EPS estimate −$0.073 → −$0.117 over 90 days. 1 up, 2 down in 30 days.

  • TrendDOWNTREND

    11% below its 50-day average.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
BlackRock, Inc.ADD993,943$6.6M
NORTHERN TRUST CORPADD169,537$1.1M
VANGUARD PORTFOLIO MANAGEMENT LLCADD123,953$816.9K
Bank of New York Mellon CorpADD62,750$413.5K
MORGAN STANLEYDOUBLED41,691$274.7K
DEUTSCHE BANK AG\ADD17,939$118.2K
RHUMBLINE ADVISERSADD16,865$111.1K
WELLS FARGO & COMPANY/MNDOUBLED16,297$107.4K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

last action Oct 2025
12-month targets · 3 analysts

Price is below the lowest target. Median implies +197%.Targets as of Oct 26, 2026.

Recent actions
DateFirmActionRating
Oct 10, 2025Jefferies
INITIATE
INITIATEBuy
Aug 26, 2025HC Wainwright & Co.
INITIATE
INITIATEBuy

Insider ledger

Form 4
$0
bought · 0 insiders
$907.2K
sold · 2 insiders
DateInsiderTypeValue
Aug 3, 2026
Kirkby Maxwell
Director
AWARD40,000 sh
Aug 3, 2026
Weston Claire
Director
AWARD40,000 sh
Jun 18, 2026
Ye Weiguo
Chief Operating Officer
SELL$19.1K
Jun 18, 2026
Ye Weiguo
Chief Operating Officer
EXERCISE$2.3K
Jun 11, 2026
Ye Weiguo
Chief Operating Officer
SELL$17.3K
Jun 11, 2026
Ye Weiguo
Chief Operating Officer
EXERCISE$2.1K
Jun 10, 2026
Ye Weiguo
Chief Operating Officer
EXERCISE$4.8K
Jun 10, 2026
Ye Weiguo
Chief Operating Officer
SELL$39.9K

Earnings setup

Estimates
Nov 18
reports in 23 days
−$0.12
EPS estimate, this quarter
−59%
estimate change, 90 days
1↑ 2↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$0.12-$0.19–-$0.06-59.1%$28.4M
Next Q-$0.12-$0.20–-$0.05-56.5%$29.5M
Current FY-$0.40-$0.61–-$0.22-37.9%$109.5M
Next FY-$0.23-$0.47–$0.00-104.3%$139.6M

Short side

FINRA· Oct 15, 2026
🔒 Subscribers only
shares short
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 22, 2026 SEC
Gyre Therapeutics entered into formal employment agreements with CEO Ying Luo and CFO Thomas Eastling on October 16…
8-K — Impact 2/10
Sep 1, 2026 SEC
Gyre Therapeutics filed an 8-K furnishing an updated corporate investor presentation. The presentation highlights the…
8-K — Impact 4/10
Aug 26, 2026 SEC
Gyre Therapeutics filed an 8-K furnishing an updated corporate presentation under Item 7.01. The presentation…
8-K — Impact 4/10
Aug 7, 2026 Earnings
Gyre Therapeutics Reports Second Quarter 2026 and Year-to-Date Financial Results and Provides Business Update
Q2 2026 revenue of $29.1 million; GAAP basic EPS: $(0.12)
Aug 3, 2026 Insider
Kirkby Maxwell was granted 40,000 shares
Director
Aug 3, 2026 Insider
Weston Claire was granted 40,000 shares
Director
Jun 30, 2026 Inst.
BlackRock, Inc. — ADD
993,943 shares ($6.6M)
Jun 30, 2026 Inst.
NORTHERN TRUST CORP — ADD
169,537 shares ($1.1M)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 18, 2026
Earnings date
GYRE Q3 2026 Earnings Scheduled — 2026-11-18
Recent
Aug 7, 2026
Earnings
Gyre Therapeutics Reports Second Quarter 2026 and Year-to-Date Financial Results and Provides Business Update
Q2 2026 revenue of $29.1 million; GAAP basic EPS: $(0.12)
May 8, 2026
Earnings date
GYRE Q1 2026 Earnings Scheduled — 2026-05-08
May 7, 2026
Earnings
Gyre Therapeutics Reports First Quarter 2026 Results and Provides Business Update
Gyre Therapeutics Reports First Quarter 2026 Results and Provides Business Update
May 4, 2026
M&A
Gyre Therapeutics Completes Acquisition of Cullgen to Create U.S.- and China-based Fully Integrated Biopharmaceutical Company
Gyre Therapeutics Completes Acquisition of Cullgen to Create U.S.- and China-based Fully Integrated Biopharmaceutical Company
Mar 12, 2026
Earnings
Gyre Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Gyre Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

SecBot reports

10 filings · 2 press releases · 1 bullish · 1 bearish · 8 neutral
All GYRE filing & press-release reports (12)